MapLight Therapeutics, Inc. MPLT
At closeNov 3, 2026, 4:02 PM EST
After hours · Nov 3, 4:02 PM ET
- YTD
- -61.24%
- 1 year
- -59.73%
- Market cap
- 378.47M
- EPS (ttm)
- -6.25
- Shares out
- 42.62M
- Forward P/E
- -10.51
- YTD return
- -61.24%
- 1-year return
- -59.73%
- Volume
- 345.18K
- Avg volume
- 497.36K
- Open
- 6.82
- Previous close
- 6.78
- Day's range
- 6.80 – 7.15
- 52-week range
- 6.77 – 40.43
- Analysts
- Strong Buy
- Price target
- 41.50 (+509.4%)
- Earnings date
- Sep 18, 2026
1M -2.36 (-25.46%)
Key statistics
- Enterprise value
- 1.48B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -95.70M
- Total cash
- 310.11M
- Total debt
- 5.59M
- Return on equity
- -80.95%
- Short % of float
- 11.72%
- 50-day average
- 30.61
- 200-day average
- 22.20
Analyst view
Consensus: strong buy
- Target (low)
- 30.00
- Target (mean)
- 41.50
- Target (high)
- 60.00
- Strong buy2
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 18, 2026
Expected Sep 18, 2026. Consensus EPS estimate -1.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 18, 2026 | Jun 30, 2026 | -1.05 | — | — | — |
| Jun 25, 2026 | Mar 31, 2026 | -0.91 | -1.34 | -0.43 | -47.25% |
| May 15, 2026 | Dec 31, 2025 | -1.05 | -1.34 | -0.29 | -27.89% |
| Dec 4, 2025 | Sep 30, 2025 | -1.72 | -37.18 | -35.46 | -2,061.63% |
| Aug 22, 2025 | Jun 30, 2025 | -0.962 | -1.14 | -0.18 | -18.50% |
| Jul 30, 2025 | Mar 31, 2025 | — | -0.54 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 10, 2026 | Needham | main | Buy | Buy |
| Jun 25, 2026 | Raymond James | init | — | Strong Buy |
| Jun 23, 2026 | Craig-Hallum | main | Buy | Buy |
| Jun 22, 2026 | Needham | main | Buy | Buy |
| Jun 2, 2026 | Stifel | main | Buy | Buy |
| May 28, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- maplightrx.com
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Maplight Therapeutics (NASDAQ:MPLT) CFO Sells $82,149.36 in Stock 
Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $93,025.04 in Stock 
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $96,024.32 in Stock 
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $124,068.40 in Stock 
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT) 
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Stock Has Consensus Price Target of $29.50 
Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround 
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics 
MapLight Therapeutics to Participate in Upcoming Investor Conference
Your note
Sign in to keep a note on MPLT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CATALYST4, INC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 27, 2025 | 0 |
| FOFF ERIN PENNOCK | Officer | Sale | May 6, 2026 | 346,059 |
| GILLIS JONATHAN | Officer | Sale | Apr 27, 2026 | 181,219 |
| HANSON KRISTOPHER | General Counsel | Sale | May 10, 2026 | 162,331 |
| KREITZER ANATOL | Officer | Sale | Apr 26, 2026 | 211,190 |
| KROEGER CHRISTOPHER A. M.D. | Chief Executive Officer | Sale | May 17, 2026 | 1,394,090 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Novo Holdings A/S | 8.65% | 3,686,622 | 144.96M | Mar 30, 2026 |
| FCPM III Services B.V. | 7.57% | 3,226,400 | 126.86M | Mar 30, 2026 |
| T. Rowe Price Investment Management, Inc. | 6.57% | 2,801,937 | 110.17M | Mar 30, 2026 |
| Goldman Sachs Group Inc | 4.68% | 1,994,873 | 78.44M | Mar 30, 2026 |
| Blackrock Inc. | 3.14% | 1,339,731 | 52.68M | Mar 30, 2026 |
| Blue Owl Capital Holdings LP | 2.36% | 1,005,929 | 39.55M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.47% | 625,724 | 24.60M | Mar 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 1.46% | 621,328 | 24.43M | Mar 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.12% | 478,579 | 18.82M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.07% | 457,576 | 17.99M | May 30, 2026 |
| -Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 0.97% | 414,063 | 16.28M | Mar 30, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 0.80% | 342,343 | 13.46M | Mar 30, 2026 |